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Aberrant hypermethylation of promoter regions in specific genes is a key event in the for-
mation and progression of cancer. In at least some situations, these aberrant alterations
occur early in the formation of malignancy and appear to be tumour specific. Multiple
reports have suggested that measurement of the methylation status of the promoter
regions of specific genes can aid early detection of cancer, determine prognosis and predict
therapy responses. Promising DNA methylation biomarkers include the use of methylated
GSTP1 for aiding the early diagnosis of prostate cancer, methylated PITX2 for predicting out-
come in lymph node-negative breast cancer patients and methylated MGMT in predicting
benefit from alkylating agents in patients with glioblastomas. However, prior to clinical
utilisation, these findings require validation in prospective clinical studies. Furthermore,
assays for measuring gene methylation need to be standardised, simplified and evaluated
in external quality assurance programmes. It is concluded that methylated genes have the
potential to provide a new generation of cancer biomarkers.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
Tumour biomarkers are potentially useful in the identification
of individuals at increased risk of developing cancer, in screen-
ing for early malignancies and in aiding cancer diagnoses. Fol-
lowing a diagnosis of cancer, biomarkers may be used for
determining prognosis, predicting therapeutic response, sur-er Ltd. All rights reserved
t of Pathology and Labor
ublin 4, Ireland. Tel.: +35
.J. Duffy).veillance following curative surgery for cancer andmonitoring
therapy (for review, see Refs. [1,2]). Currently used tumour
markers are mostly proteins that are measured in either
serum or plasma (e.g. by sandwich-type immunoassay) or in
tumour tissue (e.g. by ELISA or immunohistochemistry).1,2
The primary defect in cancer resides in genomic DNA.
Molecular alterations in DNA that contribute to cancer.
atory Medicine, Nuclear Medicine Laboratory,
3 1 2094378; fax: +353 1 2696018.
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zygosity, microsatellite instability and aberrant gene methyl-
ation.3,4 Specific genes with such abnormalities have been
suggested as potential new tumour biomarkers.5,6
Compared with other molecular structures such as mRNA,
miRNA and certain proteins, the use of DNA for the measure-
ment of tumour marker has a number of attractive features.7
Firstly, DNA molecules are very stable and in contrast to
mRNA and many proteins, can survive harsh conditions for
long periods of time. Most importantly, relatively intact DNA
can be isolated from formalin-fixed, paraffin-embedded tis-
sue. Secondly, unlike proteins, nucleic acid can be amplified
by PCR and related techniques, thus allowing measurements
on small amounts of test sample. The aim of this article is to
review the use of one form of DNA alteration in cancer, i.e.
aberrant gene promoter methylation, for the detection and
management of patients with cancer. Firstly, however, a brief
introduction to DNA methylation is presented.
2. DNA methylation
DNA methylation involves the substation of a hydrogen ion
with a methyl group at the carbon 5 position of cytosine (C)
residues, using S-adenosylmethionine as the donor molecule
(for review, see Refs. [8,9]). In mammalian cells, methylation
is mostly restricted to C residues that proceed guanine (G) res-
idues, i.e. CpG dinucleotides. In general, the CpG dinucleotide
is underrepresented in the mammalian genome but it can be
found at relatively high frequency in short genomic se-
quences, known as CpG islands.
CpG islands range in size from 0.5 to 5 kb, and have a G:C
content of at least 55% and an CpG to GpC frequency of at
least 0.65.10 CpG islands are associated with approximately
50% of mammalian genes and are mostly located in the pro-
moter and first exon regions of the gene, although occasion-
ally they are also found towards the 3 0 end.8 CpG islands are
mostly unmethylated in normal adult healthy tissues, but
can be methylated to varying extents in cancer.11 Methylation
of CpG islands in gene promoter regions is generally associ-
ated with gene silencing due to the abrogation of gene
transcription.8,9
Genomic scanning of 98 different primary tumours
showed that on average, there were approximately 600 aber-Table 1 – Methylated genes detected in preneoplastic lesions t
malignancy. HGPIN, high-grade prostate intraepithelial neopla
intraepithelial neoplasia.
Methylated gene Preneoplastic lesion
p16INK4A Barrett’s esophagus
p16INK4A In situ squamous cell carcinoma
p16INK4A In situ squamous cell carcinoma
p16INK4A, p14ARF, MGMT, APC Colorectal adenoma
hMLH1 Ulcerative colitis
hMLH1 Endometrial hyperplasia
GSTP1 HGPIN
APC, DAPK, MGMT Cirrhotic liver
14-3-3 sigma, RASSF1, APC, DAPK Atypical hyperplasia, DCIS
DAPK1, RARB, TWIST1 CIN-3rantly methylated genes per tumour.12 Indeed, genes impli-
cated in most of the steps in tumourigenesis and tumour
progression can be silenced by DNA promoter methyla-
tion.12,13 These genes include not only those encoding pro-
teins, but also those coding for microRNAs.8,9
The genes undergoing methylation during the early
phases of tumourigenesis are potential markers for identify-
ing individuals at increased risk of developing malignancy
or for aiding the diagnosis of early malignancy, while those
genes undergoing methylation during progression of malig-
nancy are potential prognostic markers. In addition, measure-
ment of the methylation status of genes involved in drug
sensitivity and/or resistance may yield therapy predictive
information.
3. Advantages of using methylated genes as
tumour biomarkers
Blood levels of most currently used protein biomarkers are
rarely increased in the early stage malignancy.1 Consequently,
most existing blood protein biomarkers are of little value in
either screening or aiding the early diagnosis of cancer. On
the other hand, aberrant methylation of the promoter regions
of multiple genes is now known to exist in both early and ad-
vanced cancers (Table 1). Release of cells or free DNA contain-
ing these aberrantly methylated genes into surrounding
luminal fluids or blood might thus permit the early detection
of cancer or the identification of individuals at high risk of
developing cancer. Some of the advantages of using methyl-
ated genes as cancer markers are now briefly discussed.
3.1. Serum concentrations of methylated genes display a
high specificity for malignancy
In contrast to the existing biomarkers, methylated genes ap-
pear to have superior specificity for cancer. In a review of
the early literature, Laird10 identified 599 hypermethylated
CpG islands in serum or plasma from 325 independent control
subjects. Remarkably, all were found to be negative for the
DNAmethylation biomarkers investigated, yielding an overall
specificity of 100%. Lower specificity, however, was found
when DNA methylation analysis was carried out on the rele-
vant luminal fluids from these subjects.10 As pointed out byhat have a high predisposition of progressing to invasive
sia; DCIS, ductal carcinoma in situ; CIN, cervical
Cancer type Refs.
Oesophageal cancer [14,15]
of lung Squamous cell lung cancer [16,17]
of cervix Squamous cell carcinoma of cervix [18]
Colorectal cancer [19,20]
Colorectal cancer [21]
Endometrial cancer [22]
Prostate cancer [23,24]
Hepatocellular cancer [25]
Breast cancer [26–28]
Cervical cancer [29]
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as the DNA methylation markers may be detecting malig-
nancy earlier than is possible with conventional diagnostic
modalities. Alternatively, the presence of DNA methylation
biomarkers in luminal fluids may reflect premalignant condi-
tions that have not yet progressed to a cancer that is detect-
able with existing diagnostic modalities. In such a scenario,
quantitative serial levels of the DNA methylation markers
may identify preneoplastic lesions that are likely to progress
to invasive malignancy.10
The high cancer specificity of methylated genes present in
blood or in other biological fluids is highly desirable if these
markers are to be used in screening for early malignancy.
False positive findings are relatively common with existing
screening procedures, leading to follow-up testing that does
not necessarily result in the diagnosis of cancer.30 Such fol-
low-up tests are costly and cause considerable mental stress
to the subjects concerned.30 Highly specific DNA methylation
markers might thus be combined with highly sensitive tests
in order to screen for cancer, e.g. in combination with PSA
for prostate cancer screening, in combination with CA 125
for ovarian cancer screening or in combination with mam-
mography for breast cancer screening, i.e. panels of tests
may be more useful in screening than single tests.
3.2. Certain genes exhibit relative tissue specificity in their
methylation pattern
Organ specificity is another desirable feature of a tumour bio-
marker, especially when used in the diagnostic setting. At
present, the only widely used organ-specific marker is PSA,
which for all practical purposes is prostate specific in man
but not prostate cancer-specific. For reasons that are not yet
clear, some genes possess significant tissue specificity in their
promoter methylation patterns. Thus, the hMLH1 gene is
methylated in colorectal31 and gastric cancers32 but is appar-
ently rarely methylated in oesophageal cancer33 and hepa-
toma,34 BRCA1 is methylated in breast and ovarian cancers
but not in many other types of cancer35, while methylation
of the p73 and p15INK4B genes appears to be present almost
exclusively in haematological malignancies.35 If confirmed
with larger studies, DNA methylation patterns might be able
to help with the identification of metastatic tumours of un-
known primary origin. Indeed, following systematic profilingTable 2 – Biological fluids and tissues in which cancer-derived
diagnostic value.
Fluid/tissue Cancer type
Sputum Lung p
Ejaculate Prostate G
Urine Prostate G
Biopsy Prostate G
Nipple fluid Breast R
Serum Breast R
Serum Ovary B
Peritoneal Ovary B
Stools Colorectum S
Serum Colorectum S
Urine Bladder Rof DNA methylation patterns in a range of different tumour
cell lines, Paz et al.36 were able to identify a specific profile
of CpG islands for each cancer type. It should be stated, how-
ever, that not all genes undergoing promoter methylation dis-
play organ specificity. For instance, methylation of the
RASSF1 and p16INK4A (also known as CDKN2A) gene promoters
is found in several types of cancer.8,9
3.3. Gene methylation is associated with defined DNA
regions
Unlike the situation with mutations in many cancer-associ-
ated oncogenes and tumour suppressor genes, gene promoter
methylation in tumours is usually found in confined genomic
regions. Consequently, one set of primers can be used to de-
tect the presence of a specific methylated gene. In contrast,
mutations in cancer-causing genes such as p53 and APC are
distributed over multiple sites,37,38 thus requiring many dif-
ferent sets of primers that add to assay complexity and ex-
pense. This lack of requirement for multiple sets of primers
for DNA methylation measurements simplifies assays design
and reduces expense.
4. Use of methylated genes as tumour
biomarkers
4.1. Identification of subjects at high risk of developing
cancer and aiding early detection of cancer
In order to be of value in identification of patients at increased
risk of cancer, screening or aiding early diagnosis of cancer, a
marker should be detectable in a biological sample that can
be obtained using a minimally invasive procedure. In addi-
tion, alterations in the marker should be specific for the rele-
vant premalignant condition or malignancy and should be
measurable in patients with early stage cancer or those with
premalignant lesions at high risk of progressing to
malignancy.
As shown in Table 2, methylated genes released from
tumour tissue can be assayed in a variety of biological
fluids.27,39–56 The measurement of the methylated genes in
these fluids for the identification of subjects at high risk of
developing cancer as well as aiding the detection of early
malignancy is discussed below.methylated genes have been shown to have potential
Methylated gene(s) Refs.
16INK4A, RASSF1, MGMT [27,39–41]
STP1 [42–45]
STP1, RASSF1A, RARß2, APC [46,47]
STP1, RARß2, APC, TIG1 [48,49]
ASSF1 [50]
ASSF1, APC, DAPK [28]
RCA1, RASSF1 [51]
RCA1, RASSF1 [51]
FRP2, CDKN2A, hMLH1 [52,53]
EPT9, TMEEF2, NGFR [54]
ASSF1 APC, p14ARF, DAPK, BCL2, TERT [55,56]
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Despite many attempts, the development of a clinically useful
protein biomarker for lung cancer has remained elusive.
Existing protein biomarkers for this disease such as CYFRA
21-1, neurone-specific enolase (NSE) and CEA lack sensitivity
and specificity and consequently, they are of little value for
early detection.57,58 One of the most frequent molecular de-
fects in lung cancer is promoter hypermethylation of several
genes (for review, see Ref. [39]). Amongst the genes shown
to be hypermethylated in this malignancy are methylguanine
methyl transferase (MGMT), p16INK4A, RASSF1A, APC, CHD13
and RARb.39 As some of these genes (e.g. p16INK4A) undergo
hypermethylation during the early phases of lung carcinogen-
esis and can be detected in cells exfoliated into surrounding
luminal fluids, they are potential markers for the early detec-
tion of lung cancer.
In one of the first studies to investigate the use of DNA
methylation markers for the early detection of lung cancer,
Palmisano et al.40 found hypermethylation of either the
p16INK4A or the MGMT gene in sputum in all 21 patients with
squamous cell carcinoma of the lung (SCCL). For 11/21 pa-
tients, sputum samples were obtained 5–36 months prior to
the diagnosis of SCCL. In all these 11 patients, hypermethyla-
tion of p16INK4A was found, the longest lead-time being 35
months. Apart from one patient with equivocal findings, spu-
tum cytology was not diagnostic. In contrast to patients with
SCC, methylation of p16INK4A and MGMTwas present in only
15% and 25%, respectively, of 123 controls without clinical evi-
dence of lung cancer. These controls, however, were at in-
creased risk of developing malignancy because of either
cigarette smoking or exposure to radon.
Kersting et al.41 also found hypermethylation of the
p16INK4A gene promoter in sputum from subjects at increased
risk of developing lung cancer, i.e. in chronic smokers. While
the p16INK4A gene was hypermethylated in 18/51 (35%) of pa-
tients with lung cancer, hypermethylation was also found in
4/25 (16%) chronic smokers. Interestingly, three of these
chronic smokers later developed malignancy. In this study, a
higher frequency of p16INK4A gene methylation was detected
in sputum from both the lung cancer patients and the chronic
smokers than in either bronchial lavage fluid or brushings
from these subjects.
In a further study on lung cancer, hypermethylation of
the RASSF1A gene promoter was found in sputum from 4/8
(50%) patients with small cell lung cancer, 5/24 (21%) in those
with non-small cell lung cancer, 4/13 (31%) chronic smokers,
one of the two former smokers but in none of six never
smokers.27 Significantly, 2/4 of the current smokers and the
one former smokers displaying RASSF1A hypermethylation
developed lung cancer within 12–14 months of the sputum
sampling.
These studies, when taken together, suggest that mea-
surement of DNA methylation markers in sputum is a prom-
ising approach for the early detection of lung cancer in
subjects at high risk of developing this disease.
4.1.2. Prostate cancer
Although controversial, PSA is widely used in screening for
prostate cancer. Indeed, elevated serum levels of PSA are
now the most common initial event leading to the diagnosisof prostate cancer.59 Because of limited specificity and sensi-
tivity, PSA, however, is a non-ideal screening test for prostate
cancer.60 A frequent molecular alteration in prostate cancer is
hypermethylation in the promoter region of the glutathione-
S-transferase P1 (GSTP1) gene. According to Goessl et al.,43
GSTP1 promoter hypermethylation constitutes an ideal
DNA-based biomarker for prostate cancer because it is pres-
ent in up to 90% of prostatic cancer tissues and in 2/3 of high
grade prostatic intraepithelial neoplasias (PIN) but is appar-
ently rarely present in benign prostate tissue.
Suh et al.45 were one of the first to show the potential of
this methylated gene for the early detection of prostate can-
cer. Using ejaculates, these investigators found methylated
GSTP1 in 4/9 patients with prostate cancer. Later, Goessl
et al.42 reported the presence of methylated GSTP1 in 23/32
(72%) of sera, in 4/8 (50%) of ejaculates and in 4/11 (36%) urine
samples from patients with prostate cancer. In contrast,
methylated GSTP1 was not detected in any body fluid investi-
gated from 26 control patients with benign prostate hypertro-
phy (BPH). In an update of this work, the sensitivity of GSTP1
was found to be 73%, when urine was collected following
prostatic massage.46
In order to further increase sensitivity, Hoque et al.47 mea-
sured the urinary DNA methylation status of RASSF1A, RARb2
and APC as well as of GSTP1. All urines from 52 patients with
prostate cancer displayed DNA methylation in one or more of
these genes. In contrast, urines from non-prostate cancer
control subjects were negative for methylation of the same
gene profile. In a more recent study, Roupret et al.49 reported
that these four methylated genes detected prostate cancer
with a sensitivity of 86%, at a specificity of 89%.
The above findings suggest that the gene methylation sta-
tus of urine, serum or ejaculate could complement PSA in the
detection of early prostate cancer. Additional markers for
prostate cancer are particularly needed for men with PSA
concentrations between 4 and 10 lg/L and in those with per-
sistently elevated PSA but negative biopsy. In the latter situa-
tion, DNA methylation profiles could be used to stratify men
into high risk or low risk groups for either repeated biopsy
or surveillance.
Rather than using fluids, Jeronimo et al.48 measured the
relative level of methylated GSTP1 DNA, i.e. ratio of GSTP1 to
MYOD1 methylation in sextant prostate biopsy samples. In
this prospective study on 21 patients with elevated PSA levels,
11 had histological confirmation of prostate cancer, while the
other 10 had no histological evidence of prostate cancer. The
median ratio of GSTP1 to MYOD1 methylation in the biopsy
samples was 410 for patients with prostate cancer compared
to 0 for those without evidence of prostate cancer. Using an
arbitrary cut-off point of 10.0, the authors correctly predicted
the histological diagnosis of prostate cancer in 10/11 (90.9%)
of the biopsies from patients with prostate cancer and ex-
cluded prostate cancer in all 10 patients whose biopsy dis-
played no evidence of cancer. Overall, DNA methylation
analysis yielded a sensitivity of 90.9%, at a specificity of
100% with a positive predictive value of 100% for detecting
prostate cancer.
If these results are confirmed, quantitation of GSTP1meth-
ylation could be of value in differentiating between non-
malignant hyperplastic lesions and prostate cancer in biopsy
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cal examination of prostate tissue.
4.1.3. Breast cancer
Currently available serum biomarkers such as CA 15-3 and
CEA are of little value for the early detection of breast cancer.
In an attempt to establish molecular diagnostic biomarkers
for this malignancy, Lewis et al.61 measured DNA promoter
methylation of RASSF1, APC, H-cadherin, RARb2 and cyclin D2
genes in fine needle biopsy samples from 27 breast cancer pa-
tients and 55 unaffected women, whose risk of breast cancer
had been defined using a number of established criteria.
Methylation of the cyclin D2 gene was found in 57% of the tu-
mour tissues but not in any benign breast tissues and in the
breast tissue of only one of the unaffected women. RARb2
gene methylation was detected in 32% of benign breast spec-
imens from cancer patients but in only 9% of similar samples
from unaffected women. Significantly, DNA promoter methyl-
ation of RASSF1 and APCwas found more frequently (70% and
56%, respectively) in breast tissues from unaffected women at
increased risk of breast cancer than in thosewith low or inter-
mediate risk of breast cancer (29% and 20%, p = 0.04 and
p = 0.03). Determination of the DNA methylation status of
RASSF1 and APC promoters might thus be useful for identify-
ing women with benign breast disease at increased risk of
developing breast cancer. On the other hand, since cyclin D2
methylation appeared to be found almost exclusively in
breast cancer, it might be exploited for the early diagnosis
of breast cancer, especially if it could be detected in serum
or nipple aspirate fluid (NAF).61
In another study on breast cancer, Krassenstein et al.50
compared DNA promoter methylation of RARb2, GSTP1,
p16INK4A, p14ARF, RASSF1 and DAP kinase in 22 matched speci-
mens of tumour tissue, normal tissue and NAF. NAF was also
obtained from five healthy women as well as fibrocystic
breast tissue from five additional women. Hypermethylation
of at least one of these genes was detected in all 22 cancers,
and an identical gene hypermethylation pattern was present
in 18/22 (82%) of matched NAFs. In contrast, DNA hyperme-
thylation was not detected in benign breast tissue or in NAF
from healthy women.
Dulaimi et al.28 measured DNA promoter methylation of
RASSF1, APC and DAPK in 34 breast cancers and found hyper-
methylation of at least one of these genes in 32 (94%) of the
samples investigated. Of these 32 patients, sera were also po-
sitive for promoter hypermethylation in 26 (76%). In contrast,
hypermethylation of RASSF1, APC or DAPK was not found in
any of 6 normal specimens of breast cancer, 6 inflammatory
breast tissue lesions, and 20 sera from healthy subjects or
in 8 sera from patients with undefined inflammatory dis-
eases. Measurement of gene hypermethylation in NAF or sera
may thus be a potential test for aiding the early detection of
breast cancer.
Hoque et al.,62 using plasma, determined the DNA methyl-
ation status of APC, GSTP1, RASSF1A and RARb2 in women
with breast cancer and controls. It was unclear if the control
group was age matched with the breast cancer patients. DNA
promoter methylation of at least one of the four genes was
present in 29/47 samples from cancer patients (sensitivity,
62%) but in only 5/38 control samples (specificity, 87%).These preliminary findings on plasma suggest that DNA-
methylated genes may be superior to CA 15-3 as markers
for breast cancer. If the above results are confirmed, methyl-
ation of specific genes might be used as an adjunct to mam-
mography in screening for breast cancer. Thus, women
found to be DNA methylation-positive for specific genes but
to be mammographically negative might undergo intensive
follow-up or magnetic resonance imaging (MRI)
investigations.
4.1.4. Ovarian cancer
CA 125, the most widely used biomarker in ovarian cancer, is
elevated in serum from approximately 80% of all patients
with this malignancy but in only about 50% of those with
early stage or FIGO stage I disease. As well as lacking sensitiv-
ity for early stage disease, CA 125 can be increased in most
types of adenocarcinomas as well as in multiple types of be-
nign diseases, both gynaecological and non-gynaecological
diseases (for review, see Ref. [63]). Similar to the situation
with PSA in prostate cancer, this lack of sensitivity and spec-
ificity limits the use of CA 125 in screening asymptomatic
subjects for ovarian cancer.63 Despite this, CA 125 in conjunc-
tion with transvaginal ultrasound is currently undergoing
evaluation as a screening modality for ovarian cancer.63
Ibanez de Caceres et al.51 showed that DNA promoter
hypermethylation of either the BRCA1 or the RASSFIA gene
was present in 34/50 (68%) of ovarian cancer tissues. The
remaining 16 tumours that lacked methylation of either
BRCA1 or RASSFIA genes displayed DNA methylation of APC,
p14, p16INK4A or DAP. An identical pattern of gene methylation
was detected in matched sera from 41/50 (82%) of patients
including 13/17 patients with FIGO stage I disease. Hyperme-
thylation was also found in 28/30 samples of peritoneal fluid
from patients with stage Ic-IV disease, including three cases
with negative or atypical cytology. Significantly, no DNA
hypermethylation of the above genes was found in non-
malignant ovarian tissues, peritoneal fluid or blood from 40
female control subjects.
4.2. Methylated genes for predicting patient outcome
For optimum management of patients with cancer, accurate
prognostic and predictive factors are necessary. Such factors
are particularly important in cancer types that have widely
varying outcomes and for which systemic adjuvant therapy
may be beneficial, e.g. lymph node-negative breast cancer
and stage II colon cancer. In both these situations, prognostic
factors may help to differentiate those patients with indolent
from those with more aggressive disease. Patients with
aggressive disease may then be candidates for treatment with
systemic adjuvant therapy, while those with indolent disease
may be spared the toxic side-effects and costs of this treat-
ment. Ideally, prognostic factors should be evaluated in the
absence of systemic adjuvant therapy. Such a study is best
carried out prospectively although a sufficiently high-pow-
ered retrospective study lacking bias should also provide reli-
able data.
In contrast to prognostic biomarkers, predictive biomark-
ers are factors that are associated with either response or
resistance to therapy.64 Predictive markers are necessary in
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widely in their response to a specific therapy. Thus, for most
cancer therapies, only a proportion of patients benefit while
many needlessly suffer from toxic side-effects. Clearly, for
optimum patient management, it is desirable to know the
likelihood of response, prior to administration of therapy.
Predictive biomarkers are most conveniently evaluated in
either the neoadjuvant or advanced disease settings, i.e.
where measurable disease is present.65 In the adjuvant set-
ting, predictive markers should be investigated as part of a
randomised trial, in which the marker is used to determine
response in the treatment arm while a potential prognostic
value can be evaluated in the control arm without systemic
treatment.
For many of the published investigations that related
methylated genes to patient outcome, it was not clear
whether a prognostic effect, a predictive effect or a combina-
tion of both was assessed. This applies particularly to studies
with early cancers that were treated with adjuvant therapy. In
the present review, we use the term predicting patient out-
come, where it is unclear whether a prognostic or predictive
impact is being observed. On the other hand, when it is clear
that a pure prognostic or predictive effect was found, we use
the appropriate term. The use of methylated genes for aiding
prognosis and therapy prediction has been most extensively
investigated in breast and brain cancers.
4.2.1. Breast cancer
One of the best validated methylated genes for predicting out-
come is PITX2 in patients with early breast cancer. Using DNA
methylation arrays, Maier et al.66 investigated the potential
ability of 117 candidate genes to predict outcome in 109
lymph node-negative ER-positive breast cancers treated with
adjuvant tamoxifen. Of the 117 genes investigated, methyla-
tion of the upstream promoter region of the PITX2 gene gave
the strongest correlation with metastasis-free survival. The
ability of the microarray method to determine outcome was
confirmed with a quantitative DNA methylation assay.66
The relationship between PITX2 DNAmethylation and out-
come in lymph node-negative ER-positive breast cancer pa-
tients treated with adjuvant tamoxifen was subsequently
validated in two independent multicentre studies. The first
of these involved extracts of frozen tumours from 236 women
treated at five different European centres,66 while the second
used paraffin-embedded tumour tissue from 399 patients
treated at 10 European centres.67 Based on the results from
these two studies, PITX2 DNA methylation is a potential bio-
marker for predicting outcome in patients with newly diag-
nosed lymph node-negative steroid hormone receptor-
positive breast cancer treated with tamoxifen monotherapy.67
As well as predicting outcome following treatment with
adjuvant tamoxifen, hypermethylation of the PITX2 gene
has also been associated with both prognosis in systemically
untreated lymph node-negative steroid hormone receptor-po-
sitive breast cancer68 and risk of developing disease recur-
rence following treatment of node-positive oestrogen
receptor-positive patients with adjuvant anthracycline-based
chemotherapy.69
DNA methylation has also been investigated for identify-
ing patients with metastatic breast cancer likely to benefitfrom specific therapies. Martens et al.,70 using a microarray-
based technology, investigated the DNA promoter methyla-
tion status of 117 genes in steroid hormone receptor-positive
tumours from 200 patients with metastatic breast cancer. Of
the 117 genes analysed, 10 were found to be significantly
associated with objective response to hormone therapy in pa-
tients with recurrent breast cancer. The predictive genes in-
cluded phosphoserine aminotransferase (PSAT), stathmin
(STNM1), S100A2, SFN, PRKCd, SYK, VTN, GRIN2D, TGFBR2 and
COX7A2L. Of these 10 genes, methylation status of the PSAT
promoter displayed the strongest association with response.
This finding was confirmed using both an independent quan-
titative DNA methylation assay and quantitative determina-
tion of PSAT mRNA.
4.2.2. Malignant gliomas
Although relatively rare, malignant gliomas are associated
with disproportionately high morbidity and mortality.71 Glio-
blastomas account for 60–70% of malignant gliomas. The
standard therapy for these tumours is surgical resection, to
the extent that it is safely feasible, radiotherapy and chemo-
therapy.71 The main chemotherapy drugs used are alkylating
agents such as carmustine and temozolomide. These drugs
act by binding to multiple sites in genomic DNA, especially
the O-6 position of guanine.72 Binding at these sites leads to
interstrand cross-linking, cytotoxicity and apoptosis. This
binding, however, can be reduced in the presence of MGMT.
Levels of MGMTmight thus be expected to correlate with sen-
sitivity to alkylating agents.72
Expression of the MGMT gene is at least partially con-
trolled by methylation at its promoter region.72 In order to test
the hypothesis that methylation at the MGMT DNA promoter
might affect response to alkylating drugs, Esteller et al.73
investigated the relationship between tumour MGMT gene
promoter methylation and response to carmustine in 47 con-
secutive patients with newly diagnosed gliomas. In this preli-
minary study, MGMT gene promoter methylation was found
in 19 (40%) of the gliomas and was associated with a better re-
sponse to chemotherapy, greater overall survival and longer
time to progression. Furthermore, MGMT promoter methyla-
tion was more predictive of outcome following carmustine
therapy than tumour grade, Karnofsky performance status
or patients age. As an untreated control arm was not included
in this study, it was not possible to determine whetherMGMT
genemethylation statuswas prognostic, predictive or both for
patients with gliomas.
Subsequent work showed that MGMT gene promoter sta-
tus was associated with outcome in glioblastoma patients
treated with an another alkylating agent, i.e. temozolomide.74
In this study on 206 patients, the presence of tumour MGMT
DNA promoter methylation predicted a favourable outcome,
irrespective of therapy administered. For patients whose tu-
mour contained a methylated MGMT promoter, a significant
survival advantage was found in those treated with temozol-
omide and radiotherapy as comparedwith those whowere gi-
ven only radiotherapy. In the absence ofMGMT DNA promoter
methylation, there was only a trend for a difference in sur-
vival between the treatment groups.
It should be pointed out that in this study, genomic DNA
for MGMT promoter methylation testing was carried out on
Table 3 – Methylated genes shown to predict outcome in cancer.
Gene(s) Malignancy Adjuvant systemic therapy Refs.
PITX2 Breast cancer Tamoxifen [66,67]
PITX2 Breast cancer None [68]
PITX2 Breast cancer Anthracyclene-based [69]
PSAT Breast cancer Tamoxifen [70]a
ESR1 (ER) Breast cancer Tamoxifen [75]
MGMT Glioma Carmustine, platinum [73]
MGMT Glioblastoma Temozolomide [74]
MGMT Diffuse large B-cell lymphoma Cyclophosphamide, vincristine, doxorubicin [76]
HOXA9, TMS9, RARb1 Neuroblastoma None [77]
p15, E-cadherin Acute myeloid leukaemia None [78]
GSTP1, APC, Cyclin D2, GSTP1 Prostate cancer None [79,80]b
MGMT, APC, ATM, p16, CDH13, RASSF1A Non-small-cell lung cancer NS or None [81–83]
HPP1, HLTF Colorectal NS [84]b
NS, not stated.
a Tumour tissue from patients with advanced cancer was investigated.
b These studies used serum rather than tumour tissue.
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collected prospectively, specimens were obtained from only
about half of the patients and were informative in only about
two-thirds of the cases analysed.74
4.2.3. Other methylated genes for predicting patient outcome
As summarised in Table 3, several other methylated genes
have been investigated for determining outcome in cancer.
Almost all these studies, however, contained relatively small
numbers of patients, were retrospective in design and have
not been validated. Furthermore, for many of these reports,
it was unclear whether a prognostic or predictive impact
had been observed.
5. Unresolved Issues in the use of methylated
genes as cancer markers
5.1. Specificity of gene methylation for malignancy
The use of methylated genes for risk identification or aiding
cancer diagnosis is based on the assumption that methylation
at specific sites in the promoter regions of certain genes is
confined to malignancy or premalignant lesions. Other fac-
tors, however, may affect gene methylation such as aging
and benign diseases.
Kwabi-Addo et al.85 examined the effect of aging on DNA
methylation in non-malignant human prostate tissue. A sig-
nificant increase in DNA promoter methylation with age
was found for several genes including RARß2, RASSF1A and
GSTP1. Another gene, i.e. MYOD1 that was shown to undergo
age-related changes in colorectal cancer,86 however, did not
exhibit age-related methylation in normal prostate.85 The
implication of these findings is that studies investigating a
potential diagnostic utility for methylated genes should as a
minimum include age-matched controls.
Certain benign diseases, especially benign tumours, may
also exhibit altered gene methylation. Little or no research
has been carried out in this area but is essential prior to gene
methylation assays being recommended for cancer screening
and/or diagnostic purposes.5.2. Unresolved analytical issues
A major unresolved analytical issue is the optimum system/
platform to be used for determining gene methylation in the
clinical setting. Currently, multiple approaches are available
formeasuring genemethylation in research laboratories.6,87–89
Some of the most commonly used methodologies, together
with their advantages and disadvantages are listed in Table 4.
According to the recent National Cancer Institute work-
shop on the clinical application of methylated DNA sequences
as cancer biomarkers, bisulphite sequencing is optimal for the
detection of CpG island methylation of new genes, pyrose-
quencing is best for quantitation of individual CpG sites while
quantitative methylation-specific PCR is best for sensitive
detection of methylated alleles.89 It is unclear which, if any,
of these will be used for routine clinical purposes. Following
selection of a specific analytical platform, assays for clinically
important methylated genes must be optimised, standardised
and must undergo technical validation including evaluation
in external quality assurance programmes.110
5.3. Requirement for clinical validation
It is clear from above thatmethylated genes are promising bio-
markers for aiding the early detection of cancer and for man-
aging patientswith diagnosedmalignancy. It should, however,
be emphasised that virtually all the published studies so far
have been small scale and retrospective in design. In order
for methylated genes to enter routine clinical use, these preli-
minary findings must be confirmed in high-level evidence
studies such as prospective trials or meta/pooled analysis of
individual data from smaller-scale studies. Furthermore, the
measurement of methylated genes must be able to provide
additional information to that available from existing diagnos-
tic, prognostic and predictive modalities. Most importantly,
the additional informationmust be clinically relevant, i.e. pro-
vide information that improves patient outcome, enhances
quality of life or leads to reduced health care costs.
In order to accelerate this clinical validation, multicentre
collaboration will be necessary and a clear pathway estab-
Table 4 – Methodologies used for determining DNA methylation pattern, together with their advantages and disadvantages. MS-MPLA, Methylation-specific multiplex
ligation-dependent probe amplification; MS-SNuPE, methylation-sensitive single nucleotide primer extension; MB-PCR, methylation binding PCR; MS-FLAG,
methylation-specific fluorescent amplicon generation; MeDIP, methylated DNA immunoprecipitation; DMH/MCAM/RLGS, differentiation methylation hybridisation/
methylated CpG island amplification/restriction land mark genomic screening; MBP, methylation binding protein; MIRA, methylated CpG island recovery assay and MS,
mass spectrometry.
Genome wide
screening
methods
Uni- or
multiplex
or genome-
wide
screening
(U/M/G)
Low or
high
throughput
(L/H)
Methylation
sensitive
restriction
Bisulfite
conversion
Methylated
CpG immuno-
precipitation
Gel based
fragment
detection
Real-time
detection
Array-
based
detection
Ultradeep
sequencer
Costl
($/$$/$$$/
$$$$)
Refs.
Methylation
sensitive restriction/
MS-MPLA
M H X X $ [86,90]
MSP/COBRA/MS-
SNuPE
U H – X X $ [91–93]
MB-PCR/COMPARE-
MS
U H X X X $$ [94,95]
Real time MSP
(Methylight/MS-
FLAG/HeavyMethyl)
U H X X $$ [96–98]
Bisulfite sequencing
/pyrosequencing
U M X X – $$ [99]
Ultradeep bisulfite
sequencing (MeDIP-
seq)
G L X – X $$$$ [100]
DMH/MCAM/RLGS G L X – X – X $$$ [101–103]
MeDIP/MBP Chip on
Chip/MIRA
G L – X – X $$$ [104–106]
Bisulphite converted
DNA on array
G/M L X – X $$$ [107]
Bisulphite converted
DNA on MS
M/U L/H X – $$ [108,109]
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that the US National Cancer Institute has formed an organisa-
tion known as the Early Detection Research Network
(EDRN).111,112 The aim of this group is to bring together the ex-
perts from academia and industry in order to promote bio-
marker discovery and validation, while also helping transfer
of this knowledge to clinical practice.
The EDRN network has also published criteria for the
development and validation of new markers for the early
detection of cancer. The first phase involves preclinical explo-
ration to help identify promising markers. Next is the devel-
opment of an assay and validation phase necessary to test
the ability of the assay to detect established disease. The third
is a retrospective and longitudinal phase to assess the new
marker’s ability to diagnose preclinical disease and to define
a ‘‘screen positive’’ rule. Following this, prospective screening
is carried out to identify the extent and characteristics of dis-
ease detected by the test, as well as the false-positive rate. In
the final phase, a definite trial, such as a prospective random-
ised study, is performed to evaluate the value of screening on
the burden of disease in the general population. These steps
that are endorsed by the PathoBiology Group of the European
Organisation for Research and Treatment of Cancer
(EORTC)110 should now be implemented to evaluate the prom-
ising new diagnostic biomarkers emerging from the research
on gene methylation in cancer.
6. Conclusion
Increasing data suggest that DNAmethylation measurements
of the promoter regions of specific genes have the potential to
supply additional or superior information to that available
from the existing cancer markers. These early finding now re-
quires validation, initially in retrospective studies but ulti-
mately in large prospective clinical studies. In addition to
clinical validation, assays for methylated genes must be ro-
bust, simple, standardised, evaluated in external quality
assurance schemes and made available at affordable costs.
Only then, can patients expect to benefit from measurement
of these markers.
Finally, with the approaching era of personalised medi-
cine, the link between biomarkers and therapy will be en-
hanced.113,114 In this context, it should be stated that a
number of therapies directed against methylated genes are
now in clinical use.8 Thus, the hypomethylating agents 5-aza-
cytidine and 5 0aza-2 0deoxycytidine have been approved for
the treatment of specific leukaemia and the myelodysplastic
syndrome. While these demethylating agents are non-specific
with respect to their target gene(s), the aim in the future will
be to develop drugs that target specific methylated genes
causally involved in malignancy such as tumour suppressor
genes and genes encoding miRNAs.8,9 Whether specific DNA
methylation patterns in tumour cells will be able to predict re-
sponse to these agents remains to be determined.Conflict of interest statement
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